Biocontrol has now been advised of the intention to grant a patent by the European Patent Office for the aerosol delivery technology inlicensed in 2007 from the United Kingdom Health Protection Agency

Biocontrol's CSO, Dr. David Harper today presented a plenary address to the Edinburgh International Phage Conference, entitled "Phage therapy: Raising the bar on the clinical work".

 Featured in the Financial Times written by Jonathan Guthrie

http://www.ft.com/cms/s/0/53a92418-44ad-11dd-b151-0000779fd2ac.html

Featured in The Daily Express, written by Maisha Frost.

Scientists at Biocontrol Ltd have today presented at the Bacteriophage 2008 meeting in Hertfordshire a first look at the results of their initial Phase II clinical trial.

Scientists at Biocontrol, leading the world in developing new treatments to cure serious antibiotic-resistant infections, have secured a £250,000 investment from The Capital Fund.

The awards ceremony was held to recognise the achievements of the London award winners for 2007.

The BBC Radio 4 programme "The Rise of Resistance", broadcast today, features coverage of Biocontrol's clinical trial of its bacteriophage therapeutic against ear infections caused by Pseudomonas aeruginosa.

Biocontrol today announced the signing of an in-licensing agreement with the UK Health Protection agency.

Biocontrol receives Development Award under the Grant for Research and Development Scheme from the London Development Agency

Biocontrol today announced the first treatment of a patient in its double-blind, placebo controlled phase1/2 clinical trial targeting ear infections caused by Pseudomonas aeruginosa.

Biocontrol today announced the closing of its investment round which is to provide funding for its first clinical trial.